## Increasing the Efficiency of Biosimilar Development Programs— Reevaluating the Need for Comparative Clinical Efficacy Studies

## Workshop Agenda

Soccion 1 (Dublic):						
Session 1 (Public):	ing comparative clinical efficacy studies (CFS) in					
Setting the stage—How have we been using comparative clinical efficacy studies (CES) in biosimilar development programs, and what have we learned?						
Tuesday, September 12, 2023						
	1200 - 1600 Central European Time (CET)					
7:00 am – 10:00 am Eastern Time (US & Canada); 1300 – 1600 Central European Time (CET)  Welcome/Opening Remarks (10 min)  Carol Kim and Brooke DalSanto, US FDA						
Regulatory Experience and Considerations to	Regulatory Agency Speakers					
Date (110 min)	Marie-Christine Bielsky, MHRA					
	Hye-Na Kang, WHO					
	Rene Anour, EMA					
	Bradley Scott, Health Canada					
	Ryosuke Kuribayashi, PMDA					
	Woo-Yong Oh, MFDS					
Domal ORA (FO main)	Stacey Ricci, US FDA					
Panel, Q&A (50 min)	Moderator: Ali Al Homaidan, SFDA					
Closing Remarks (10 min)	Carol Kim, US FDA					
Session 2 (Public):  Stakeholder perspectives on the need for Wednesday, September 13, 2023 7:00 am – 10:00 am Eastern Time (US & Canada);	· · ·					
Welcome Day 2 (5 min)	Brooke DalSanto, US FDA					
Stakeholder Experience with and Perspectives	Stakeholder Representative Speakers					
on CES (120 min)	Martin Schiestl, Sandoz					
	Gillian Woollett, Samsung					
	<ul><li>Gillian Woollett, Samsung</li><li>Fabrice Romanet, Fresenius-Kabi</li></ul>					
	Fabrice Romanet, Fresenius-Kabi					
	<ul><li>Fabrice Romanet, Fresenius-Kabi</li><li>Keith Watson, KRW Bio Reg Solutions</li></ul>					
	<ul> <li>Fabrice Romanet, Fresenius-Kabi</li> <li>Keith Watson, KRW Bio Reg Solutions</li> <li>Elena Wolff-Holz, Biocon</li> </ul>					
	<ul> <li>Fabrice Romanet, Fresenius-Kabi</li> <li>Keith Watson, KRW Bio Reg Solutions</li> <li>Elena Wolff-Holz, Biocon</li> <li>Elena Guillen, Hospital Clinic de Barcelona</li> </ul>					
<b>Panel, Q&amp;A</b> (45 min)	<ul> <li>Fabrice Romanet, Fresenius-Kabi</li> <li>Keith Watson, KRW Bio Reg Solutions</li> <li>Elena Wolff-Holz, Biocon</li> </ul>					

## Session 3-5 (Regulators only):

Regulatory considerations regarding efficient use of comparative clinical efficacy studies in biosimilar development programs

Tuesday-Thursday, September 19-21, 2023

7:00 am-10:00 am Eastern Time (US & Canada); 1300 – 1600 Central European Time (CET)